Language Selector:

Contact

Lungpacer Medical, Inc. Presents at Respiratory Innovation Summit, May 2019, Dallas, Texas

Lungpacer Medical, Inc., CEO Doug Evans presented preclinical and clinical research on Lungpacer’s novel phrenic nerve pacing technology at the 2019 RIS Meeting. The Respiratory Innovation Summit unites the innovators, investors and clinicians who are leading the fight to create powerful new treatments for deadly and crippling diseases of the lungs and airways.

Linkedin Twitter Youtube

© 2024 Lungpacer Medical Inc. ®

The AeroPace System is approved by the United States Food and Drug Administration to improve weaning success in adult patients on MV at least 96 hours and who have not weaned. The AeroPace System is not approved in any other country.

CAUTION: The AeroNova System is limited by Federal law (United States) to investigational use. Used exclusively for clinical investigations.

Lungpacer® Medical, AeroPace® System and AeroNova® System are registered trademarks of Lungpacer Medical.